ArticleCureus2024
Diagnostic Performance of Cystatin C in the Early Detection of Diabetic Kidney Disease at the University of Nigeria Teaching Hospital, Ituku-Ozalla.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Predictive value of the C-reactive protein-to-lymphocyte ratio for prognosis in heart failure patients with acute kidney injury.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is an increase in the prevalence of diabetes mellitus (DM) globally. Individuals with diabetes mellitus are at higher risk of impairment of kidney function. This study evaluated the diagnostic performance of Cystatin C in the early detection of diabetic kidney disease (DKD).
methodsAcross a sectional analytical study of 300 participants (200 study group and 100 control group). A relevant clinical history was obtained, and a physical examination was carried out. Venous blood was collected to assay for serum creatinine, serum albumin, serum cystatin C, serum urea, fasting blood glucose, and urine for the quantification of urine albumin excretion rate.
resultsThe median age of the study group versus the control group was 62.50 for DM with proteinuria, 60.00 for DM without proteinuria, and 60.00 years for the control group (F = 3.524, p = 0.172). The laboratory parameters that were higher in the study group compared to the control group were FBG (141.0, 130, vs. 104 mg/dl, F = 68.456, p = <0.001), serum creatinine (109.0, 88.5, vs. 105.0 umol/l, F = 35.50, p = <0.001), serum cystatin C (1.24, 1.11, vs. 0.84 mg/L, F = 59.27, p = <0.001), and urine albumin excretion (230.0, 102.0, vs. 30.0 mg, F = 128.62, p = <0.001). The diagnostic performance of cystatin C using MDRD and cystatin C eGFR <60ml/min/1.73m2 was 13% and 23%, respectively, for the study group without proteinuria. Also, when the diagnostic efficiency of the variables was compared using ROC, the AUC of creatinine eGFR (MDRD) was less than that of cystatin C eGFR between the cut-off levels of 30 mg and 300 mg of urine albumin excretion. Cystatin C eGFR had a strong negative correlation with urine albumin excretion when compared to creatinine eGFR (MDRD).
conclusionThis study showed the diagnostic performance of serum cystatin C in the early detection of DKD and that cystatin C-derived eGFR is more sensitive than serum creatinine-derived eGFR in detecting DKD early in people with DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.